Overview
LXRX market data
Price History
LXRX price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.14 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.05 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -37.5% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $1.03 – $2.68 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $1B · P/B 3.89 · P/S 15.01.
Company News
Lexicon Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q2 financial results.Benzinga · Aug 6, 2026, 12:46 PM
Lexicon Pharmaceuticals Q2 EPS $(0.07) Misses $(0.05) Estimate, Sales $692.000K Miss $3.998M EstimateBenzinga · Aug 6, 2026, 11:48 AM
8-K filing — LEXICON PHARMACEUTICALS, INC. (LXRX)SEC EDGAR · Aug 6, 2026, 11:33 AM
Lexicon Pharmaceuticals Completes Randomization Of Patients In Its Pivotal Phase 3 'Sotagliflozin In Patients With Symptomatic Obstructive And Non-Obstructive Hypertrophic Cardiomyopathy' Clinical TrialBenzinga · Jul 27, 2026, 12:35 PM
Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific SessionsGlobenewswire Inc · Jun 3, 2026, 12:15 PM
Navigating Life with Hypertrophic CardiomyopathyGlobenewswire Inc · May 14, 2026, 6:15 PM